Dr. Saar Gill, Chair of ASGCT's Advancing Gene and Cell Therapies for Cancer Planning Committee, spoke with us about the discussions he anticipates happening between attendees and speakers at this upcoming symposium. "I particularly enjoy asking challenging questions and encouraging the participants, the audience, to really challenge the speakers," said Dr. Gill. "This isn't just about sitting back and listening." Hear more from Dr. Gill below and register for Advancing Gene + Cell Therapies for Cancer to join next week's discussion, live or online! www.asgct.org/advancing #cancertreatment #celltherapy #genetherapy #ASGCTAdvancing24
American Society of Gene & Cell Therapy
Non-profit Organizations
Waukesha, WI 29,799 followers
ASGCT is the primary membership organization for professionals working in gene and cell therapy.
About us
The American Society of Gene & Cell Therapy is the primary professional membership organization for gene and cell therapy. The Society's members are scientists, physicians, patient advocates, and other professionals. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, and biotechnology and pharmaceutical companies. The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. ASGCT's strategic vision is to be a catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.
- Website
-
http://www.asgct.org
External link for American Society of Gene & Cell Therapy
- Industry
- Non-profit Organizations
- Company size
- 11-50 employees
- Headquarters
- Waukesha, WI
- Type
- Nonprofit
- Founded
- 1996
Locations
-
Primary
20800 Swenson Dr.
Suite 300
Waukesha, WI 53186, US
Employees at American Society of Gene & Cell Therapy
-
Ravishankar Vadali
-
Serene Forte, PhD, MPH
Rare Diseases | Genetic Medicines | Medical Affairs | Strategy and Leadership | Business Development | Commercialization
-
Aravind Asokan
Professor, Duke University; Biotech Founder
-
Ahmed S. MOUSA, MD
Executive | Strategy | Business Development | Democratize Innovation | Biotech Ecosystem Catalyst | Cell & Gene Therapy | Rare Diseases | Precision…
Updates
-
Columbia University launches groundbreaking initiative in cell engineering and therapy, led by CAR T-cell pioneer and ASGCT past-president, Michel Sadelain, MD, PhD. Key points: - Dr. Sadelain, past president and current member of ASGCT, appointed to head the Columbia Initiative in Cell Engineering and Therapy (CICET) - Focus on advancing cell and gene therapies for cancer, autoimmune diseases, and genetic disorders - Initiative to create synergies with existing Columbia research programs Aims to attract leading scientists and enhance research infrastructure - Dr. Sadelain to also direct Cancer Cell Therapy Initiative at Columbia's Herbert Irving Comprehensive Cancer Center Read the entire article, written by Aleka Gomez-Sotomayor-Roel, here: https://lnkd.in/eY465jSQ This initiative marks a significant step in expanding #celltherapy applications, potentially transforming treatments for a wide range of diseases. #cgt #ASGCT #cellandgenetherapy
-
ASGCT has submitted a series of comment letters addressing critical payment policy changes to advance the accessibility of innovative therapies. These letters are part of ASGCT's ongoing efforts to advocate for policies that enhance patient access to life-saving treatments and promote the development of cell and gene therapies (#CGTs). The letters outline key recommendations to both the Outpatient Prospective Payment System (OPPS) and Physician Fee Schedule (PFS): ▪ OPPS Comment Letter: ASGCT supports Centers for Medicare & Medicaid Services’ proposal to exclude #celltherapy and #genetherapy treatments from C-APC packaging methodology. In the proposed rule, CMS notes that gene and cell therapies are generally not ancillary to the primary service involved in their administration. ASGCT agrees, as the therapies are typically the core intervention involved in any procedure in which they are associated. ASGCT encourages CMS to finalize the proposal. Furthermore, ASGCT encourages CMS to extend the policy indefinitely. ▪ PFS Comment Letter: CMS proposes to establish payment under the Physician Fee Schedule for four new CPT codes for services related to the administration of CAR-T cell therapies. CGTs are unique therapies that require a multi-step administration process. This process includes the collection of a patient’s cells, treatment of the cells, and administration of the cells. In addition to these steps, providers offer care to patients for all the associated impact of patients receiving these therapies. ASGCT appreciates the 2025 proposed rule, CMS includes some proposed changes that recognize the complexity of the full process associated with administering CAR-T cell therapies. #ASGCTadvocacy
-
📣 Calling all cancer researchers, clinicians, and industry professionals! 📣 The clock is ticking, but there's still time to be part of something extraordinary. The Advancing Gene + Cell Therapies for Cancer conference is happening NEXT WEEK, October 16-17, in Philadelphia (and online). What to expect: 🔬 Nearly 40 brand-new cancer-focused abstracts 🔬 Cutting-edge discussions on gene and cell therapies for cancer 🔬 Networking opportunities with speakers and fellow attendees 🔬 Option to attend in person or virtually Whether you're in academia, clinical practice, or industry, this conference is your gateway to the latest advancements in cancer treatment. We hope to see you next week! Register now at www.asgct.org/advancing #ASGCTAdvancing24 #Cancertreatment #Celltherapy #Genetherapy
-
NEW on the blog: #GeneticTesting not only confirms diagnoses, but also identifies specific genetic variants that are essential for determining a patient’s eligibility for certain #genetherapy and #celltherapy treatments. Read the post to learn about the role of gentic testing in Duchenne #musculardystrophy (#DMD), giant axonal neuropathy (#GAN), and #AngelmanSyndrome. WATCH: Visit our #PatientEducation site to check out the latest Community Quick Takes module on this topic that includes video interviews with Lauren B., Kevin Flanigan, Diana Bharucha-Goebel, and Kimberly Goodspeed, MD! https://lnkd.in/gZ_f8PQ9
-
🔊The countdown to #ASGCTBreakthroughs24 is on!🔊 TEN DAYS until early registration rates expire for Breakthroughs in Muscular Dystrophy, our inaugural hybrid event with the Muscular Dystrophy Association! Secure your registration today to get the best rates for this event Nov. 19-20 in Chicago and virtually! You won't want to miss the opportunity to explore the latest research on #genetherapy and #celltherapy treatments for various forms of #musculardystrophy. https://lnkd.in/gScKs6ZS
-
Saar Gill, MD, PhD, discusses one of the sessions that he is looking forward to at Advancing Gene + Cell Therapies for Cancer. Anticipated to be a "spirited discussion," the session called "CAR Integration and T Cell Malignancies" will host speakers Frederic Bushman, PhD, and Stephen Schuster, MD, and will cover lentiviral integration through clinical observations. Advancing Gene + Cell Therapies aims to be highly interactive and focused on fostering an engaging dialogue between attendees and speakers. Join us Oct. 16-17, in person or online. Visit www.asgct.org/advancing to register and to view the full program. #cancertreatment #ASGCTAdvancing24 #CGT #celltherapy #genetherapy
-
Congratulations to Victor Ambros (UMass Chan Medical School) and Gary Ruvkun (Harvard Medical School + Massachusetts General Hospital) who will receive The Nobel Prize in Physiology or Medicine! Drs. Ambros and Ruvkun are being awarded for the discovery of microRNA and its role in post-transcriptional gene regulation. MicroRNA (or #miRNA) is small, non-protein coding RNA that targets mRNA to regulate expression of genes. Their groundbreaking discovery revealed a completely new principle of gene regulation that turned out to be essential for multicellular organisms, including humans. #NobelPrize https://lnkd.in/eFU7DuZf
The Nobel Prize in Physiology or Medicine 2024
nobelprize.org
-
#CellTherapy is the transfer of specific cell type(s) into a person to treat or prevent disease, but how does it work? The source of the cells used for cell therapy come from one of two places: ➖Autologous cell therapy means the cells used are from the person's own body. The cells are removed, modified outside the body and then returned to the body. ➖Allogeneic cell therapy means the cells are from someone other than the patient. Learn about cell therapy's potential benefits, challenges, and more on our #PatientEducation site. https://lnkd.in/g5CDXQ_U
-
Volunteer opportunity reminder: Review #ASGCT2025 abstracts! We're looking forward to receiving your research next month for possible presentation at the 28th Annual Meeting, but we need your help selecting the most impactful work. Volunteer to review Annual Meeting abstracts by filling out this form on our website! https://lnkd.in/gcXfhSnd